Second Sight Medical Products, Inc. (EYES) News
Filter EYES News Items
EYES News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest EYES News From Around the Web
Below are the latest news stories about SECOND SIGHT MEDICAL PRODUCTS INC that investors may wish to consider to help them evaluate EYES as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayWe're starting the final day of trading this week with a look at the biggest pre-market stock movers for Friday and what's moving them! |
Second Sight Medical Products, Inc. Announces Shareholder Approval for Proposed Merger with Nano Precision Medical, Inc. and other Results of 2022 Annual MeetingLOS ANGELES, July 29, 2022--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held on July 27, 2022, where the quorum was present. The formal results of the vote are included in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission. |
Second Sight Medical Products Announces Year Four NIH Funding of its Orion StudyLOS ANGELES, July 18, 2022--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prostheses that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company received notice from the National Institutes of Health ("NIH") of the release of year four funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (the "Orion Trial"), grant 5UH3NS103442. |
Nano Precision Medical Co-Founder and CEO Discusses Proposed Second Sight Merger in Interview to Air on Bloomberg U.S. on the RedChip Money Report®LOS ANGELES, April 14, 2022--Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight"), a recognized global leader in neuromodulation devices for blindness, today announced that an interview with Adam Mendelsohn, Ph.D., Co-Founder and CEO of Nano Precision Medical, Inc. ("NPM"), will air on The RedChip Money Report® on Bloomberg US on April 16 at 7 p.m. Eastern Time (ET). Bloomberg US is available in an estimated 73 million homes across the United States. |
EYES Stock Pops on Biotech Merger Plans. 5 Things to Know.Second Sight Medical (NASDAQ:EYES) stock is up 15% this morning after announcing a merger with Nano Precision. Source: Shutterstock So what do you need to know? To start, Second Sight Medical is acquiring Nano Precision through an all-stock deal. As part of this, it will issue 134 million shares. Current EYES stock holders will own roughly 23% of the combined company. Right now, Second Sight expects the deal to close by the end of the third quarter. Before it does, it will be subject to stockhol |
Second Sight Medical To Merge With AstraZeneca-Backed Nano Precision MedicalSecond Sight Medical Products Inc (NASDAQ: EYES) will acquire privately-held Nano Precision Medical Inc in an all-stock transaction. Second Sight Medical develops implantable visual prosthetics. Under the agreement, Nano Precision Medical will merge with a wholly-owned subsidiary of Second Sight. The surviving company Nano Precision Medical will be owned by Second Sight. The newly-formed merged company will focus on developing innovative implants for chronic diseases. The combined company will b |
Second Sight Medical Products and Nano Precision Medical Announce Merger Agreement to Create Leading Therapeutic Implant CompanyLOS ANGELES & EMERYVILLE, Calif., February 07, 2022--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or "Second Sight") and Nano Precision Medical, Inc. ("NPM"), today announced that they have entered into a definitive agreement under which privately held NPM will merge with a wholly owned subsidiary of Second Sight in an all-stock transaction. NPM will be the surviving company and owned by Second Sight. The resulting company will focus on development of innovative drug and dev |